Aribio Lab raises $13M placement, making Aribio its top shareholder
What's the deal? Aribio Lab has secured an US$15.1M private placement to fund operations, improve its financial structure, and deepen partnerships, the company disclosed on September 16. The round makes Aribio its largest shareholder.
Who's investing? Two backers are taking part: Aribio, which is contributing roughly US$12.6M for 4,330,254 new shares, and Aribio HoldingsDealroom has a profile for this one. Try Dealroom →, which is investing about US$2.52M for 866,050 shares.
The details: The placement issues 5,196,304 new shares at US$2.9 each, with payment due on November 30. Once completed, Aribio will hold a 15.90% stake, while Aribio Holdings becomes the second-largest shareholder at 14.10% — a combined 30%.
Why now? The deal follows expanding research collaboration between Aribio and Aribio Lab. Aribio is running a global Phase 3 trial for AR1001, an oral Alzheimer's disease candidate, and recently began co-developing an Alzheimer's vaccine with Aribio Lab.
What's the endgame? Aribio Lab plans to use the capital for research and business expansion while broadening its work with Aribio on Alzheimer's treatments and vaccines.
The signal: The placement tightens the ties between the two firms, folding Aribio Lab further into a shared push on Alzheimer's therapeutics as the flagship AR1001 program advances through late-stage trials.
Image credit: Generated with Gemini
